Prevention and treatment of ocular side effects with a cyclosporin

Abstract

Therapeutic methods are disclosed herein.

1 - 11 . (canceled) 
     
     
         12 . A method comprising administering an ophthalmically acceptable emulsion comprising cyclosporin A to a mammal that has ceased receiving a therapeutically active agent, wherein the therapeutically active agent comprises rimantadine hydrochloride, and wherein the method is effective in treating abnormal lacrimation. 
     
     
         13 . The method of  claim 12 , wherein the ophthalmically acceptable emulsion comprises cyclosporin A at a concentration of about 0.05%. 
     
     
         14 . The method of  claim 13 , wherein the ophthalmically acceptable emulsion further comprises castor oil, polysorbate 80, and high molecular weight co-polymers of acrylic acid and a long chain alkyl methacrylate cross-linked with allyl ethers of pentaerythritol. 
     
     
         15 . The method of  claim 13 , wherein the abnormal lacrimation is associated with keratoconjunctivitis. 
     
     
         16 . The method of  claim 13 , wherein the abnormal lacrimation is the result of keratoconjunctivitis. 
     
     
         17 . The method of  claim 15 , wherein the keratoconjunctivitis is associated with the therapeutically active agent. 
     
     
         18 . The method of  claim 16 , wherein the keratoconjunctivitis is associated with the therapeutically active agent. 
     
     
         19 - 24 . (canceled)